Cited 5 times in
Immunotherapeutic restoration in HIV-infected individuals
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김준명 | - |
dc.contributor.author | 한상훈 | - |
dc.date.accessioned | 2014-12-20T16:27:12Z | - |
dc.date.available | 2014-12-20T16:27:12Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 1750-743X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/92744 | - |
dc.description.abstract | While the development of combined active antiretroviral therapy (cART) has dramatically improved life expectancies and quality of life in HIV-infected individuals, long-term clinical problems, such as metabolic complications, remain important constraints of life-long cART. Complete immune restoration using only cART is normally unattainable even in cases of sufficient plasma viral suppression. The need for immunologic adjuncts that complement cART remains, because while cART alone may result in the complete recovery of peripheral net CD4+ T lymphocytes, it may not affect the reservoir of HIV-infected cells. Here, we review current immunotherapies for HIV infection, with a particular emphasis on recent advances in cytokine therapies, therapeutic immunization, monoclonal antibodies, immune-modulating drugs, nanotechnology-based approaches and radioimmunotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 247~267 | - |
dc.relation.isPartOf | IMMUNOTHERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Anti-HIV Agents/therapeutic use* | - |
dc.subject.MESH | Antiretroviral Therapy, Highly Active/methods | - |
dc.subject.MESH | HIV Infections/drug therapy* | - |
dc.subject.MESH | HIV Infections/immunology* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunotherapy/methods* | - |
dc.title | Immunotherapeutic restoration in HIV-infected individuals | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | June Myung Kim | - |
dc.contributor.googleauthor | Sang Hoon Han | - |
dc.identifier.doi | 10.2217/IMT.10.91 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00953 | - |
dc.contributor.localId | A04286 | - |
dc.relation.journalcode | J01040 | - |
dc.identifier.eissn | 1750-7448 | - |
dc.identifier.pmid | 21322762 | - |
dc.subject.keyword | cytokine therapy | - |
dc.subject.keyword | HIV | - |
dc.subject.keyword | immune-modulating drugs | - |
dc.subject.keyword | immunotherapy | - |
dc.subject.keyword | monoclonal antibodies | - |
dc.subject.keyword | nanotechnology-based approaches | - |
dc.subject.keyword | radioimmunotherapy | - |
dc.subject.keyword | therapeutic immunization | - |
dc.contributor.alternativeName | Kim, June Myung | - |
dc.contributor.alternativeName | Han, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Kim, June Myung | - |
dc.contributor.affiliatedAuthor | Han, Sang Hoon | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 3 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 247 | - |
dc.citation.endPage | 267 | - |
dc.identifier.bibliographicCitation | IMMUNOTHERAPY, Vol.3(2) : 247-267, 2011 | - |
dc.identifier.rimsid | 28730 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.